
Get the Scoop: Elevation Oncology’s Third Quarter 2024 Financial Results and Exciting Business Achievements!
Elevation Oncology Announces Promising Phase 1 Data for EO-3021 Exciting Developments in Cancer Treatment Recently, Elevation Oncology, Inc. shared exciting news about the positive results from the initial Phase 1 data of EO-3021. The data highlighted a remarkable 42.8% confirmed overall response rate (ORR) observed in the Claudin 18.2-enriched subset of gastric and gastroesophageal junction…